ASB12: A Potential Drug Target and Biomarker for Diseases (G142689)

Target Name: ASB12

NCBI ID: G142689

ASB12

ASB12: A Potential Drug Target and Biomarker for Diseases

ASB12 (FLJ39577) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the Asparagine/Glutamyl Transferase (ASBT) family, which is involved in the regulation of protein synthesis and turnover in the cell. ASB12 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Targeting

ASB12 has been identified as a potential drug target due to its involvement in several cellular processes that are associated with the development of disease. One of the primary targets of ASB12 is the regulation of protein synthesis and turnover. ASB12 has been shown to play a role in the transfer of asparagine residues from the cytoplasm to the endoplasmic reticulum, which is a critical step in the regulation of protein synthesis.

In addition to its role in protein synthesis, ASB12 is also involved in the regulation of cell growth and differentiation. Studies have shown that ASB12 has been shown to play a role in the regulation of cell proliferation and the maintenance of stem cell self-renewal.

Another potential drug target for ASB12 is its role in the regulation of cell survival. Studies have shown that ASB12 is involved in the regulation of cell survival and that its levels are often decreased in diseases that are associated with poor cell survival, such as cancer.

Biomarker

ASB12 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The levels of ASB12 have been shown to be altered in these diseases, which suggests that it may be a useful indicator of the severity or progression of these conditions.

In addition to its potential as a drug target, ASB12 has also been shown to be a potential biomarker for several diseases. For example, studies have shown that ASB12 levels are often decreased in individuals with cancer and that its levels are often elevated in individuals with neurodegenerative diseases. In addition, ASB12 has been shown to be involved in the regulation of immune function, which suggests that it may be a useful indicator of the immune response to disease.

Conclusion

In conclusion, ASB12 is a protein that is involved in several cellular processes that are associated with the development and progression of various diseases. Its potential as a drug target and biomarker makes it an attractive target for research into the treatment of these diseases. Further studies are needed to fully understand the role of ASB12 in the regulation of protein synthesis, cell growth and differentiation, and cell survival, as well as its potential as a biomarker for disease.

Protein Name: Ankyrin Repeat And SOCS Box Containing 12

Functions: Probable substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins

The "ASB12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASB12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets